Source: ERJ Open Res, 4 (1) 00080-2017; 10.1183/23120541.00080-2017
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Iwona Pranke, Laure Bidou, Natacha Martin, Sandra Blanchet, Aurélie Hatton, Sabrina Karri, David Cornu, Bruno Costes, Benoit Chevalier, Danielle Tondelier, Emmanuelle Girodon, Matthieu Coupet, Aleksander Edelman, Pascale Fanen, Olivier Namy, Isabelle Sermet-Gaudelus, Alexandre Hinzpeter. Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons. ERJ Open Res, 4 (1) 00080-2017; 10.1183/23120541.00080-2017

Member's Comments

No comment yet.

Related content which might interest you: Factors associated with delay in treatment initiation for pulmonary tuberculosis Source: ERJ Open Res, 6 (1) 00161-2019; 10.1183/23120541.00161-2019 Year: 2020 Factors affecting progression of lung disease among patients with cystic fibrosis Source: International Congress 2019 – Physiology of cystic fibrosis Year: 2019 Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018 Examining the effects of the Gly551Asp mutation on CT outcomes in children with cystic fibrosis Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring Year: 2017 Potential risk factors for poor outcomes post-lung transplant for cystic fibrosis Source: International Congress 2019 – Lung transplantation: from basic science to clinical outcomes Year: 2019 Questions of predicting and preventing the progression of pneumofibrosis in children with cystic fibrosis Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 Factors influencing exercise performance in adults with cystic fibrosis Source: Annual Congress 2010 - Physical activity, exercise regimes and outcomes for chronic respiratory disease Year: 2010 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Pulmonary fibrosis associated with TINF2 gene mutation: is somatic reversion required? Source: Eur Respir J 2014; 44: 270-271 Year: 2014 Pulmonary fibrosis associated with TINF2 gene mutation: is somatic reversion required? Source: Eur Respir J 2014; 44: 269-270 Year: 2014 Oral health and some risk factors in children with cystic fibrosis Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012 Should the D1152H variant be included in cystic fibrosis newborn screening programmes? Source: Virtual Congress 2020 – Cystic fibrosis Year: 2020 Regulation of the response to stop mutation read-through by the nonsense mediated decay mechanism Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver? Year: 2007 Premature vascular ageing in cystic fibrosis Source: Eur Respir J 2009; 34: 1217-1218 Year: 2009 Early deaths in cystic fibrosis: Analysis of causes and risk factors in a pediatric cohort Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012 Prevalence, risk factors and prognosis of pulmonary hypertension in cystic fibrosis Source: Annual Congress 2011 - Cystic fibrosis: new basic, clinical and bacteriological knowledge Year: 2011 Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis Source: Eur Respir J 2011; 37: 59-69 Year: 2011 Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005